Back to search

Article

Defining biologically directed therapy target signatures in urothelial carcinoma: A transcriptomic framework for precision therapy

2026-06-25

Abstract excerpt

<h4>Introduction</h4> Nectin-4 targeting antibody-drug conjugate (ADC) enfortumab vedotin (EV), in combination with pembrolizumab, is the first-line treatment for patients with locally advanced or metastatic urothelial carcinoma (UC). Optimal treatment strategies for patients who are non-responders or progress on EV with pembrolizumab remain an unmet clinical need. We sought to characterize ADC and immunotherapy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b695fa39-fff2-5538-b212-bc592aadefb8
DOI
10.64898/2026.06.24.734314
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Defining biologically directed therapy target signatures in urothelial carcinoma: A transcriptomic framework for precision therapyDOI 10.64898/2026.06.24.734314
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.Semantic proximity
Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysisSemantic proximity
Associations of TACSTD2/ TROP2 and NECTIN‐4/ NECTIN ‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohortsSemantic proximity
A Five-Gene Stromal-EMT Signature Predicts Prognosis, Immunotherapy Resistance, and Therapeutic Vulnerability in Bladder CancerSemantic proximity
TROP2 expression is associated with early stage and favorable prognosis in Upper tract urothelial carcinomaSemantic proximity
Identification of tumor antigens and immune subtypes of bladder cancer for mRNA vaccine developmentSemantic proximity
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 ExpressionSemantic proximity
TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinomaSemantic proximity
Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypesSemantic proximity
Integrated analysis of single-cell and bulk RNA sequencing predicts prognosis and therapeutic response using malignant epithelial cells marker genes in bladder cancerSemantic proximity
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerSemantic proximity
Select a neighboring publication to make it the new centre.